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Abstract
Objective: To estimate the prevalence of Generalized Anxiety Disorder (GAD) symptoms among 
adults with diagnosed HIV (PWH) in the United States in order to inform effective HIV prevention 
and care efforts.
Design: The Medical Monitoring Project (MMP) is a complex sample survey of adults with 
diagnosed HIV in the United States.
Methods: We used MMP data collected during 6/2015–5/2016 to calculate the weighted 
prevalence of GAD symptoms among PWH (N=3654) and prevalence ratios with predicted 
marginal means to evaluate significant differences between groups.
Results: The estimated prevalence of GAD symptoms among PWH was 19%. GAD symptoms 
were associated with significantly lower antiretroviral therapy prescription and adherence, medical 
HIV care engagement, and sustained viral suppression. Persons with GAD symptoms were over 3 
times as likely to have an unmet need for mental health services (23% vs. 7%) and had 
significantly more emergency room visits and hospitalizations than those without these symptoms. 
GAD symptoms were associated with significantly higher prevalence of condomless sex while not 
sustainably virally suppressed with a person not known to be taking preexposure prophylaxis (9% 
vs. 6%).
Conclusions: GAD symptom prevalence among PWH was considerably higher than among the 
U.S. general adult population, indicating an excess burden of anxiety among PWH. Outcomes 
along the HIV care continuum were poorer, and risk for HIV transmission was higher, among 
persons with symptoms. Incorporating routine screening for GAD in HIV clinical settings may 
help improve health outcomes, reduce HIV transmission, and save healthcare costs.
Corresponding author and contact for requests for reprints: Linda Beer, PhD, Division of HIV/AIDS Prevention, Centers for Disease 
Control and Prevention, 1600 Clifton Rd. NE, MS-E46, Atlanta, GA 30329, Office: 404.639.5268, Fax: 404.639.8640, 
LBeer@cdc.gov.
Author contributions: Dr. Beer took the lead role in study conception and drafting the manuscript. Dr. Tie analyzed the data. All 
authors were involved in acquisition of the data, interpretation of the data, and critically revising the manuscript.
Publisher's Disclaimer: Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily 
represent the views of the Centers for Disease Control and Prevention. Portions of this work were presented at the National HIV 
Prevention Conference in March 2019 in Atlanta, GA, USA.
HHS Public Access
Author manuscript
AIDS. Author manuscript; available in PMC 2020 September 01.
Published in final edited form as:
AIDS. 2019 September 01; 33(11): 1781–1787. doi:10.1097/QAD.0000000000002286.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Human Immunodeficiency Virus; HIV; Generalized Anxiety Disorder; HIV care continuum; 
mental health
Introduction
Anxiety disorders are the most common mental disorders in the United States, and are 
associated with significant physical, mental, and social costs [1, 2]. Generalized Anxiety 
Disorder (GAD) is a type of anxiety disorder characterized by persistent and excessive 
worry that is difficult to control [3]. Evidence suggests that GAD may be more common 
among persons living with HIV (PWH) compared with others and, among PWH, is 
associated with nonadherence to HIV medications, which can lead to virologic rebound and 
subsequent increased morbidity and HIV transmission [4, 5]. Despite the importance of 
assessing need for anxiety disorder treatment in order to ensure effective HIV prevention and 
care, we lack national prevalence estimates of symptoms consistent with a diagnosis of GAD 
among PWH in the United States. Moreover, little is known about the associations between 
these symptoms and sociodemographic, clinical, and behavioral characteristics among this 
population, which can inform delivery of needed treatment. In order to fill these gaps, we 
analyzed data from the Medical Monitoring Project (MMP), a national population-based 
HIV surveillance system that produces annual, cross-sectional estimates of behavioral and 
clinical characteristics of adults with diagnosed HIV in the United States.
Methods
Detailed methods for MMP data collection are reported elsewhere [6], but briefly, MMP 
used a 2-stage sampling design. During the first stage, 23 jurisdictions were sampled from 
all U.S. states, the District of Columbia, and Puerto Rico. During the second stage, simple 
random samples of persons with diagnosed HIV aged 18 years and older were drawn for 
each participating state/territory from the National HIV Surveillance System (NHSS), a 
census of persons with diagnosed HIV in the United States. Data were collected via phone 
or face-to-face interviews and medical record abstractions during June 2015 through May 
2016. Response rates were 100% at the state/territory level and 40% at the person level. Data 
were weighted on the basis of known probabilities of selection and were adjusted for non-
response [7]. For the non-response adjustment, weighting classes were based on variables 
related to person-level response: sex at birth, HIV exposure category, and the person’s 
frequency of receipt of care (as indicated by HIV-related laboratory test results in NHSS). 
Further, the data were post-stratified to NHSS population totals by age, race/ethnicity, and 
gender. MMP data collection is part of routine public health surveillance and was 
determined to be non-research. Informed consent was obtained from all interviewed 
participants.
We calculated the weighted prevalence and associated 95% confidence interval of symptoms 
consistent with a GAD diagnosis among PWH (N=3654), overall and by selected 
sociodemographic characteristics. The Generalized Anxiety Disorder Scale (GAD-7), a 
validated 7-item scale used to screen for and measure the severity of GAD symptoms over 
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the past 2 weeks, was administered to participants by a trained interviewer. The GAD-7 asks 
the following questions: “Over the last 2 weeks, how often have you been bothered by any of 
the following problems?” for problems such as “feeling nervous, anxious, or on edge” and 
“not being able to stop or control worrying”. Response categories were “not at all”, “several 
days”, “more than half the days” and “nearly every day”, with points 0–3 assigned to each 
response category, respectively. Scores were summed to produce a total score between 0 and 
21. GAD symptoms reflecting moderate to severe anxiety were defined as a score of ≥10, 
consistent with GAD-7 scoring recommendations [8].
We compared the prevalence of clinical and behavioral characteristics among those with and 
without GAD symptoms using prevalence ratios with predicted marginal means to evaluate 
significant differences between groups. Statistical significance for all tests was defined as 
p<0.05. All analyses accounted for the complex sample design and weights.
All examined covariates were self-reported and measured over the 12 months prior to 
interview, except where otherwise noted. Homelessness was defined as living on the street, 
in a shelter, in a single room occupancy hotel, or in a car. Persons were classified as men 
who have sex with men (MSM), women who only have sex with men (WSM) and men who 
only have sex with women (MSW) based on sexual behavior among the sexually active and 
reported sexual orientation among the non-sexually active. All persons not classified as 
MSM, WSM, or MSW were grouped into the “other” category. Household poverty level was 
determined using Health and Human Services poverty guidelines. Disability included 
physical, mental, and emotional disabilities. Intimate partner violence (IPV) was defined as 
having been slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a 
romantic or sexual partner. Sexual violence was defined as having been threatened with 
harm or physically forced to have unwanted vaginal, anal, or oral sex. HIV stigma was based 
on a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 
dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, 
and perceived public attitudes about people living with HIV [9]. Responses to the items on 
the Patient Health Questionnaire (PHQ-8) were used to define “major or other depression” 
according to criteria from the DSM-IV [10]. Ancillary services for which unmet needs were 
assessed included dental care, HIV case management services, medicine through the AIDS 
Drug Assistance Program (ADAP), Supplemental Nutrition Assistance Program (SNAP) or 
Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), mental 
health services, adherence support services, transportation assistance, meal or food services, 
shelter or housing services, HIV peer group support, patient navigation services, drug or 
alcohol counseling or treatment, interpreter services, and domestic violence services. Binge 
drinking was defined as having ≥5 alcoholic beverages in a single sitting (≥4 for women) on 
at least 1 day during the 30 days before the interview. Sex that increases the risk of HIV 
transmission was defined as vaginal or anal sex with at least 1 HIV-negative or unknown 
status partner while not sustainably virally suppressed, a condom was not used, and the 
partner was not known to be taking PrEP (PrEP use was only measured among the 5 most 
recent partners and was reported by the PWH). Information from NHSS was used to 
determine whether the person had ever reached HIV disease stage 3, defined according to 
CDC’s 2014 revised surveillance case definition for HIV infection [11]. Clinical 
characteristics captured by medical record abstraction at the person’s most frequent source 
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of HIV care included documentation of antiretroviral therapy (ART) prescription and 
sustained viral suppression (all viral load measurements documented undetectable or <200 
copies/mL). HIV care engagement was defined as having received at least two elements of 
outpatient HIV care at least 90 days apart. Receipt of outpatient HIV care was measured 
through medical record abstraction and defined as any documentation of the following: 
encounter with an HIV care provider (could also be self-reported), viral load test result, CD4 
test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or 
MAC prophylaxis. Persons currently taking ART were asked about their adherence to ART 
in the 30 days before the interview using questions from a 3-item scale that ranges from 
0-100, with a score of 100 indicating perfect adherence [12].
Results
The estimated prevalence of GAD symptoms among persons with diagnosed HIV in the 
United States was 19% (Table 1). Symptom prevalence was significantly higher among 
women compared with men, and among those with a high school education or less, living in 
poverty, and recently homeless. One-third of persons experiencing recent homelessness 
reported GAD symptoms. Persons with a disability were over four times as likely to have 
GAD symptoms compared with those with no disability (33% vs. 8%). Persons who had 
experienced recent intimate partner violence and those who experienced recent sexual 
violence were each over twice as likely to have GAD symptoms as those who did not 
recently experience that form of violence (41% vs. 18% and 43% vs. 19%, respectively). 
Persons with GAD symptoms also reported significantly higher median HIV-related stigma 
scores (55%, 95% confidence interval [CI] 52-59) than those with no symptoms (35%, CI 
33-36) (data not shown in table).
GAD symptoms were associated with significantly lower antiretroviral therapy prescription 
and adherence, HIV care engagement, and sustained viral suppression (Table 2). Persons 
with GAD symptoms were over 7 times as likely to report depression symptoms (75% vs. 
11%) and over 3 times as likely to have an unmet need for mental health services (23% vs. 
7%) compared with those without GAD. Persons with GAD symptoms also had significantly 
more emergency room visits and hospitalizations than those without these symptoms.
Persons with GAD symptoms reported significantly higher levels of smoking and injection 
and non-injection drug use compared with those without symptoms. Persons with GAD 
symptoms were nearly twice as likely to inject drugs as those without symptoms. GAD 
symptoms were associated with significantly higher prevalence of condomless sex while not 
sustainably virally suppressed with an HIV-negative or unknown status partner who was not 
known to be taking preexposure prophylaxis (9% vs. 6%).
Discussion
We estimate that nearly 1 in 5 PWH in the United States experienced recent symptoms 
consistent with a diagnosis of GAD. This is the first estimate of the national prevalence of 
GAD symptoms among persons with HIV. Other U.S.-based estimates of GAD among PWH 
have ranged between 0-60%, although these studies vary widely in measurement, geography, 
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and population coverage [4]. Our estimate is similar to a recent estimate of the prevalence of 
GAD in one U.S. HIV clinic (23%) [13], and is considerably higher than the estimated 2.7% 
of U.S. adults estimated to have GAD in the past year [3], indicating an excess burden of 
anxiety among PWH compared with the general population.
The significance of the excess burden of anxiety among PWH is compounded by our finding 
that GAD symptoms are related to suboptimal HIV care engagement and outcomes in this 
population, which few studies have examined. Similar to other studies, we found that GAD 
symptoms were associated with lower ART prescription, adherence, and viral suppression 
[5, 13], which in addition to increasing morbidity can also increase the risk of HIV 
transmission. Further, this is the first analysis we are aware of to document that persons with 
GAD were more likely to have a disability, experience HIV-related stigma, be less engaged 
in HIV care, utilize the ER, and be hospitalized compared with persons without GAD. Given 
the elevated prevalence of GAD symptoms among PLW and the association between 
symptoms and poorer HIV outcomes, sex that increases the risk of HIV transmission, and 
higher use of ER care and hospitalizations, incorporating routine screening for GAD in 
clinical settings and assessing its effect on adherence may help improve health outcomes, 
reduce HIV transmission, and save healthcare costs. Comorbid depression was common 
among PWH reporting GAD symptoms, as has commonly been found among the general 
population [1]. Although anxiety and depression symptoms often co-occur, they have been 
found to have distinct dimensions and independent effects on health [8]. This may be a 
valuable area for future research on anxiety and depression among PWH. Importantly, we 
found that nearly one quarter of persons with GAD symptoms reported an unmet need for 
mental health treatment, indicating a substantial need to improve delivery of these services 
for this group.
Our analysis supports the findings of others on the relationship between GAD and social 
determinants of health such as poverty and housing instability [14–16]. Strategies to address 
anxiety among disadvantaged populations can involve interventions to increase resilience 
and stress management skills [14], although some have argued for the development of more 
robust anti-poverty interventions that could have more widespread and sustained effects 
[17]. We found a strong association between lifetime and recent experiences of sexual 
violence and intimate partner violence with GAD symptoms. Adverse life experiences such 
as these have often been found to be related to GAD [15, 16, 18, 19]. Healthcare providers, 
particularly those providing primary care, can play an important role in screening for partner 
abuse and comorbid anxiety [20]. Because most HIV care providers also provide primary 
care [21] and many work in settings with on-site ancillary services [22], they can identify 
patients in need of support and provide referrals to treatment and services.
We also documented the association between GAD symptoms and behaviors that increase 
the risk of HIV transmission such as injection drug use and sex without a condom while not 
sustainably virally suppressed. Studies have generally found a positive association between 
substance use and anxiety [4], although the causal pathways have yet to be fully determined 
and causality may be cyclical. Regardless, improving access to substance use treatment and 
HIV/STD risk reduction services could be beneficial for persons experiencing anxiety 
symptoms.
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Collaborative care models—in which medical, mental health, and case management staff 
partner to provide comprehensive care—have been found to be more effective than usual 
care in improving anxiety in patients [23]. The Ryan White HIV/AIDS Program (RWHAP) 
provides such collaborative care in “medical home” settings for un- and under-insured 
persons with HIV, which may help alleviate GAD symptoms and improve health outcomes. 
The RWHAP-funded AIDS Education and Training Centers (AETCs) National HIV 
Curriculum stresses the importance of clinician screening for anxiety and the integration of 
mental health into HIV primary care, and supports co-located services, embedded mental 
health providers, collaborative care, and decision support tools to achieve these aims [24]. 
The AETC National Resource Center developed a resource, the “Integrating Mental Health 
and Substance Use Care into HIV Primary Care Toolkit,” that can help organizations 
increase their capacity to provide these services in an HIV clinical care setting [25].
The limitations of this analysis include that the GAD-7 is not equivalent to a clinical 
diagnosis. However, the GAD-7 is one of the few anxiety measures that is linked to the 
Diagnostic and Statistics Manual of Mental Health Disorders 4th Edition (DSM-IV), and has 
been found to have good criterion validity with a clinical diagnosis of GAD using DSM-IV 
diagnostic criteria. Nevertheless, recommendations are that persons with a GAD-7 score 
indicating anxiety should be administered a formal diagnostic interview [24]. Our estimates 
of persons with moderate to severe GAD symptoms may underreport GAD diagnoses, since 
successfully treated persons may be free of symptoms. In addition, due to MMP’s cross-
sectional design, we cannot assess causality. Given our findings on the associations between 
anxiety and intimate partner and sexual violence, future research could explore the causal 
links between these phenomena and possible overlap with post-traumatic stress disorder 
among PWH. In addition, elucidation of the causal pathways linking anxiety symptoms to 
conditions such as homelessness and poverty could be promising areas for further research.
Almost 1 in 5 PWH in the United States experienced recent symptoms indicative of GAD. 
GAD symptoms were associated with greater socioeconomic, physical, and mental health 
challenges and experiences of violence. Outcomes along the HIV care continuum were 
poorer among persons with symptoms, and these persons were more likely to engage in 
sexual behaviors that carry a risk of HIV transmission. Our findings suggest a need to 
improve access to mental health counseling and treatment for this population to improve 
their health outcomes and decrease the likelihood of HIV transmission.
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